Insider Selling: Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Director Sells 4,300 Shares of Stock

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Director Lynn A. Tetrault sold 4,300 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $50.01, for a total transaction of $215,043.00. Following the transaction, the director now owns 3,000 shares in the company, valued at $150,030. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Rhythm Pharmaceuticals Stock Up 2.6 %

Shares of NASDAQ RYTM opened at $47.29 on Friday. Rhythm Pharmaceuticals, Inc. has a twelve month low of $20.97 and a twelve month high of $53.92. The stock has a market cap of $2.88 billion, a price-to-earnings ratio of -10.21 and a beta of 2.04. The company’s fifty day moving average is $46.05 and its 200-day moving average is $42.82.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last posted its earnings results on Tuesday, August 6th. The company reported ($0.55) earnings per share for the quarter, topping the consensus estimate of ($0.71) by $0.16. Rhythm Pharmaceuticals had a negative return on equity of 221.65% and a negative net margin of 254.88%. The firm had revenue of $29.08 million for the quarter, compared to analyst estimates of $28.79 million. During the same period in the previous year, the company posted ($0.82) earnings per share. The company’s revenue for the quarter was up 51.3% on a year-over-year basis. On average, research analysts anticipate that Rhythm Pharmaceuticals, Inc. will post -4.4 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have issued reports on RYTM. Bank of America cut shares of Rhythm Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $49.00 to $42.00 in a research note on Wednesday, May 8th. Needham & Company LLC reaffirmed a “buy” rating and set a $55.00 price objective on shares of Rhythm Pharmaceuticals in a research note on Wednesday, August 7th. Finally, Canaccord Genuity Group dropped their price objective on Rhythm Pharmaceuticals from $80.00 to $79.00 and set a “buy” rating for the company in a report on Wednesday, May 8th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $55.83.

Hedge Funds Weigh In On Rhythm Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. CWM LLC lifted its stake in Rhythm Pharmaceuticals by 62.6% in the second quarter. CWM LLC now owns 657 shares of the company’s stock valued at $27,000 after buying an additional 253 shares in the last quarter. AJOVista LLC bought a new stake in Rhythm Pharmaceuticals in the 4th quarter valued at $42,000. ORG Partners LLC acquired a new position in Rhythm Pharmaceuticals in the 2nd quarter worth $51,000. Quarry LP bought a new position in Rhythm Pharmaceuticals during the 4th quarter worth about $69,000. Finally, Quest Partners LLC raised its stake in shares of Rhythm Pharmaceuticals by 513.3% in the 2nd quarter. Quest Partners LLC now owns 1,662 shares of the company’s stock valued at $68,000 after purchasing an additional 1,391 shares during the period.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.